Sildenafil
Sildenafil, in the form sold as Revatio, is a phosphodiesterase 5 (PDE5) inhibitor. The US label for pulmonary arterial hypertension (PAH) (WHO Group I) lists, in adults, improving exercise ability and delaying clinical worsening and, separately, in pediatric patients 1 to 17 years old, improving exercise ability. This page covers the pulmonary arterial hypertension use. Sildenafil also has a separate US label for erectile dysfunction, which this page does not describe. The label says sildenafil inhibits an enzyme, PDE-5, in the smooth muscle of the lung blood vessels.
Also called Sildenafil citrate · Revatio
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 136411 (RxNorm also holds 221161, sildenafil citrate). MeSH D000068677 is named Sildenafil Citrate, with Sildenafil among its entry terms (a lookup on 2026-11-18, hash only), and carries no scope note, so it is recorded as an exact match for identity only. The openFDA label record for Revatio lists a UNII for the citrate, which is not recorded for the substance. RxClass lists the established pharmacologic class Phosphodiesterase 5 Inhibitor, so the record is filed under the PDE5 inhibitor page for pulmonary hypertension. The label read is the Viatris Specialty LLC label for Revatio, applications NDA203109, NDA022473 and NDA021845, effective 2024-12-18 in openFDA. The adult and pediatric statements sit in separate claims and contexts. The Viagra label (NDA020895, Viatris Specialty LLC, effective 2023-11-17) was read only for its first indication sentence. A maternal atlas page for sildenafil exists and is a separate record. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says sildenafil is an inhibitor of cGMP specific PDE-5 in the smooth muscle of the pulmonary vasculature.
Claims and evidence
Context Adults with pulmonary arterial hypertension, as described in the US label of Revatio
- Recipient
- Adult
- Population
- Adults with pulmonary arterial hypertension (PAH) (WHO Group I), as the label states.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the label states
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Adults with pulmonary arterial hypertension (PAH) (WHO Group I), as the label states.
- Excluded
- None stated
The US label of Revatio (sildenafil citrate, Viatris Specialty LLC, applications NDA203109, NDA022473 and NDA021845; the version dated 2024-12-18 in openFDA) lists treating pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening.
Applies to Adult Adults with pulmonary arterial hypertension, as described in the US label of Revatio
- Certainty method
- Not assessed
- Limitations
- This claim is tied to the Revatio label for pulmonary arterial hypertension. The substance also has separate labels for other uses, which are not recorded here. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists a pediatric use, which sits in a separate claim.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA203109.
- Retrieved
- Source effective date
- 2024-12-18
- Source state
- Current
- Version fingerprint
26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20241218.
- Retrieved
- Source effective date
- 2024-12-18
- Source state
- Current
- Version fingerprint
26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (Q-K30-SIL-LB-03, Q-K30-SIL-LB-04).
- Retrieved
- Source effective date
- 2024-12-18
- Source state
- Current
- Version fingerprint
26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Pediatric patients 1 to 17 years old with pulmonary arterial hypertension, as described in the US label of Revatio
- Recipient
- Child
- Population
- Pediatric patients 1 to 17 years old with pulmonary arterial hypertension (PAH) (WHO Group I), as the label states.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Pediatric patients 1 to 17 years old, as the label states
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Pediatric patients 1 to 17 years old with pulmonary arterial hypertension (PAH) (WHO Group I), as the label states.
- Excluded
- None stated
The same US label of Revatio separately lists treating pulmonary arterial hypertension (PAH) (WHO Group I) in pediatric patients 1 to 17 years old, to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, a measure of pulmonary hemodynamics.
Applies to Child Pediatric patients 1 to 17 years old with pulmonary arterial hypertension, as described in the US label of Revatio
- Certainty method
- Not assessed
- Limitations
- This claim is tied to the Revatio label for children aged 1 to 17 years. It says nothing about newborns or children under 1 year. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The adult indication sits in a separate claim.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA203109.
- Retrieved
- Source effective date
- 2024-12-18
- Source state
- Current
- Version fingerprint
26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20241218.
- Retrieved
- Source effective date
- 2024-12-18
- Source state
- Current
- Version fingerprint
26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (Q-K30-SIL-LB-05, Q-K30-SIL-LB-06).
- Retrieved
- Source effective date
- 2024-12-18
- Source state
- Current
- Version fingerprint
26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Pregnancy, lactation and children
The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.
In newborns, infants and children 1
The same US label of Revatio separately lists treating pulmonary arterial hypertension (PAH) (WHO Group I) in pediatric patients 1 to 17 years old, to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, a measure of pulmonary hemodynamics.
Applies to Child Pediatric patients 1 to 17 years old with pulmonary arterial hypertension, as described in the US label of Revatio
Population, setting and follow-up
- Pediatric patients 1 to 17 years old with pulmonary arterial hypertension (PAH) (WHO Group I), as the label states.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Pediatric patients 1 to 17 years old, as the label states
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- This claim is tied to the Revatio label for children aged 1 to 17 years. It says nothing about newborns or children under 1 year. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The adult indication sits in a separate claim.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA203109.
- Retrieved
- Source effective date
- 2024-12-18
- Source state
- Current
- Version fingerprint
26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20241218.
- Retrieved
- Source effective date
- 2024-12-18
- Source state
- Current
- Version fingerprint
26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (Q-K30-SIL-LB-05, Q-K30-SIL-LB-06).
- Retrieved
- Source effective date
- 2024-12-18
- Source state
- Current
- Version fingerprint
26e9c561e175bef513bd821641ad152bb98e750a93e0c2ac4f5c4c0204defedb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists pulmonary arterial hypertension (WHO Group I) in adults, to improve exercise ability and delay clinical worsening, as an indication: Pulmonary arterial hypertension
Applies to Adult Adults with pulmonary arterial hypertension, as described in the US label of Revatio
The US label of Revatio (sildenafil citrate, Viatris Specialty LLC, applications NDA203109, NDA022473 and NDA021845; the version dated 2024-12-18 in openFDA) lists treating pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening.Limitations. This claim is tied to the Revatio label for pulmonary arterial hypertension. The substance also has separate labels for other uses, which are not recorded here. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists a pediatric use, which sits in a separate claim.
-
Claim, not a settled fact FDA label separately lists pulmonary arterial hypertension in pediatric patients 1 to 17 years old as an indication: Pulmonary arterial hypertension
Applies to Child Pediatric patients 1 to 17 years old with pulmonary arterial hypertension, as described in the US label of Revatio
The same US label of Revatio separately lists treating pulmonary arterial hypertension (PAH) (WHO Group I) in pediatric patients 1 to 17 years old, to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, a measure of pulmonary hemodynamics.Limitations. This claim is tied to the Revatio label for children aged 1 to 17 years. It says nothing about newborns or children under 1 year. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The adult indication sits in a separate claim.
Record details
- Record id
cardio:sildenafil- Content hash
c8b03238726a3a5664c5c6bc1af234a820ad820ea08662ca335fe75f0146eab3